Battery-Powered Oxygen Gel Prevents Diabetic Amputations in Animal Tests

Chronic wounds affect 12 million people globally each year, with roughly one in five patients ultimately requiring amputation. These stubborn injuries, defined as wounds that remain open longer than a month, are becoming increasingly common as populations age and diabetes rates rise. The core problem lies in oxygen deprivation deep within damaged tissue, which traps wounds in prolonged inflammation and prevents proper healing.

UC Riverside researchers have developed a revolutionary solution: a battery-powered gel that delivers continuous oxygen directly where it's needed most. The soft, flexible material contains water and an antibacterial choline-based liquid. When connected to a small hearing aid-sized battery, it functions as a miniature electrochemical device that splits water molecules and steadily releases oxygen over time.

Unlike surface treatments, this gel adapts to wound contours, filling gaps where oxygen levels are lowest and infection risk highest. The system maintains oxygen flow for up to a month, supporting the weeks-long process of new blood vessel formation essential for healing.

In animal studies using diabetic and older mice whose wounds mirror human chronic injuries, results were dramatic. Untreated wounds failed to close and often proved fatal, while gel-treated wounds healed completely in approximately 23 days with full animal survival when patches were replaced weekly.

This innovation could significantly reduce amputation rates and healthcare costs while improving quality of life for millions. The technology may also advance lab-grown organ development, where consistent oxygen delivery remains a major challenge.